<?xml version='1.0' encoding='utf-8'?>
<document id="28876959"><sentence text="Chirality and neuropsychiatric drugs: an update on stereoselective disposition and clinical pharmacokinetics of bupropion."><entity charOffset="112-121" id="DDI-PubMed.28876959.s1.e0" text="bupropion" /></sentence><sentence text="1" /><sentence text=" Bupropion, an antidepressant drug has been approved as a racemate containing equal amounts of R- and S-enantiomers" /><sentence text=" Recently, the chirality of bupropion has received significant attention in the delineation of stereoselective pharmacokinetic (PK) and disposition data"><entity charOffset="28-37" id="DDI-PubMed.28876959.s4.e0" text="bupropion" /></sentence><sentence text=" Although the non-stereoselective metabolism of bupropion was well established, the emerging data suggest that bupropion exhibits complex stereoselective metabolism, leading to the formation of various stereoisomeric metabolites"><entity charOffset="48-57" id="DDI-PubMed.28876959.s5.e0" text="bupropion" /><entity charOffset="111-120" id="DDI-PubMed.28876959.s5.e1" text="bupropion" /><pair ddi="false" e1="DDI-PubMed.28876959.s5.e0" e2="DDI-PubMed.28876959.s5.e0" /><pair ddi="false" e1="DDI-PubMed.28876959.s5.e0" e2="DDI-PubMed.28876959.s5.e1" /></sentence><sentence text=" Along with the chiral PKs of bupropion, hydroxybupropion, threohydrobupropion and erythrohydrobupropion, the metabolism data also provided insights into the roles of both CYP2B6 and CYP2C19 enzymes in the stereoselective disposition"><entity charOffset="30-39" id="DDI-PubMed.28876959.s6.e0" text="bupropion" /><entity charOffset="41-57" id="DDI-PubMed.28876959.s6.e1" text="hydroxybupropion" /><entity charOffset="59-78" id="DDI-PubMed.28876959.s6.e2" text="threohydrobupropion" /><entity charOffset="83-104" id="DDI-PubMed.28876959.s6.e3" text="erythrohydrobupropion" /><pair ddi="false" e1="DDI-PubMed.28876959.s6.e0" e2="DDI-PubMed.28876959.s6.e0" /><pair ddi="false" e1="DDI-PubMed.28876959.s6.e0" e2="DDI-PubMed.28876959.s6.e1" /><pair ddi="false" e1="DDI-PubMed.28876959.s6.e0" e2="DDI-PubMed.28876959.s6.e2" /><pair ddi="false" e1="DDI-PubMed.28876959.s6.e0" e2="DDI-PubMed.28876959.s6.e3" /><pair ddi="false" e1="DDI-PubMed.28876959.s6.e1" e2="DDI-PubMed.28876959.s6.e1" /><pair ddi="false" e1="DDI-PubMed.28876959.s6.e1" e2="DDI-PubMed.28876959.s6.e2" /><pair ddi="false" e1="DDI-PubMed.28876959.s6.e1" e2="DDI-PubMed.28876959.s6.e3" /><pair ddi="false" e1="DDI-PubMed.28876959.s6.e2" e2="DDI-PubMed.28876959.s6.e2" /><pair ddi="false" e1="DDI-PubMed.28876959.s6.e2" e2="DDI-PubMed.28876959.s6.e3" /></sentence><sentence text=" Furthermore, the metabolism studies also suggested specific involvement of CYP2B6 pathway in the stereoselective hydroxylation of bupropion to R,R-hydroxybupropion, which was considered as a better marker for CYP2B6 activity"><entity charOffset="131-140" id="DDI-PubMed.28876959.s7.e0" text="bupropion" /><entity charOffset="146-164" id="DDI-PubMed.28876959.s7.e1" text="R-hydroxybupropion" /><pair ddi="false" e1="DDI-PubMed.28876959.s7.e0" e2="DDI-PubMed.28876959.s7.e0" /><pair ddi="false" e1="DDI-PubMed.28876959.s7.e0" e2="DDI-PubMed.28876959.s7.e1" /></sentence><sentence text=" 2" /><sentence text=" Other significant learnings were: (1) understanding the in vivo CYP2D6 inhibitory potential of bupropion with respect to the chirality of parent drug and the metabolites; (2) the potential involvement of bupropion and metabolites towards significant down regulation of CYP2D6 mRNA; (3) significant in vivo CYP2D6 inhibitory activity (86%) exhibited by R,R-hydroxybupropion and threohydrobupropion"><entity charOffset="96-105" id="DDI-PubMed.28876959.s9.e0" text="bupropion" /><entity charOffset="205-214" id="DDI-PubMed.28876959.s9.e1" text="bupropion" /><entity charOffset="378-397" id="DDI-PubMed.28876959.s9.e2" text="threohydrobupropion" /><pair ddi="false" e1="DDI-PubMed.28876959.s9.e0" e2="DDI-PubMed.28876959.s9.e0" /><pair ddi="false" e1="DDI-PubMed.28876959.s9.e0" e2="DDI-PubMed.28876959.s9.e1" /><pair ddi="false" e1="DDI-PubMed.28876959.s9.e0" e2="DDI-PubMed.28876959.s9.e2" /><pair ddi="false" e1="DDI-PubMed.28876959.s9.e1" e2="DDI-PubMed.28876959.s9.e1" /><pair ddi="false" e1="DDI-PubMed.28876959.s9.e1" e2="DDI-PubMed.28876959.s9.e2" /></sentence><sentence text=" 3" /><sentence text=" The newly published data on chiral PKs and disposition of bupropion and its metabolites can be used to gauge the drug-drug interaction potential when bupropion is combined in clinical therapy"><entity charOffset="59-68" id="DDI-PubMed.28876959.s11.e0" text="bupropion" /><entity charOffset="151-160" id="DDI-PubMed.28876959.s11.e1" text="bupropion" /><pair ddi="false" e1="DDI-PubMed.28876959.s11.e0" e2="DDI-PubMed.28876959.s11.e0" /><pair ddi="false" e1="DDI-PubMed.28876959.s11.e0" e2="DDI-PubMed.28876959.s11.e1" /></sentence><sentence text=" Moreover, such data would be useful to understand the consequences (if any), due to the combination of bupropion with other drugs both from a safety and efficacy perspective because of the prevalence of polypharmacy situations in many therapeutic areas including CNS indications"><entity charOffset="104-113" id="DDI-PubMed.28876959.s12.e0" text="bupropion" /></sentence><sentence text="" /></document>